Anti-Obesity Agents

DBCAT000472Pharmacologic class

Agents that increase energy expenditure and weight loss by neural and chemical regulation. Beta-adrenergic agents and serotoninergic drugs have been experimentally used in patients with non-insulin dependent diabetes mellitus (NIDDM) to treat obesity. A DrugBank category of 18 drugs. 12 of them are approved.

Also known as: Agents, Anti-Obesity · Agents, Antiobesity · Agents, Weight-Loss · Anti Obesity Agents · Anti Obesity Drugs
Drugs: Aclimostat
Amlintide
Benfluorex
Cathine
Cetilistat
Diethylpropion
Exenatide
Oleoyl-estrone
Orlistat
Perflubron
Phenmetrazine
Phentermine
Phenylpropanolamine
Rimonabant
Semaglutide
Setmelanotide
Sibutramine
Topiramate

What you can answer from here — as of August 24, 2016

18DrugsEach linked to its full drug card

Listed above

34Drug targetsEvery drug–target pair in the class, with bond type

3,097Marketed productsAcross the regions we cover, with dosage forms and routes

5Routes of administrationHow the drugs in this class are given

Which targets do Anti-Obesity Agents share, and which companies have late-stage candidates in this class?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account